Multi-Fused Ring Compound for Diabetes, Obesity

USPTO published patent application US20260098037A1 for a pharmaceutical compound containing a multi-fused ring structure intended for treating diabetes and obesity-related diseases. The application claims priority to filing date September 22, 2025, and includes CPC classifications in C07D (organic chemistry) and A61K (pharmaceutical preparations). The application specifies compounds of formula (I), stereoisomers, and pharmaceutically acceptable salts, along with pharmaceutical compositions and methods of preparation.

For pharmaceutical companies and biotech firms developing metabolic disorder treatments, this published application establishes prior art as of its filing date. Parties should conduct freedom-to-operate analyses before advancing similar compounds through development. The publication makes the claimed subject matter publicly accessible, enabling competitors to assess potential overlap with their own R&D programs and adjust strategies accordingly.